Standing note

Promising and proven are different words.

Virtual Vitalis provides education on peptides, sells 0 of them, sources 0 of them, and recommends 0 vendors.

Virtual Vitalis sells 0 peptides, takes 0 commissions from any pharmacy or supplement brand, and runs 0 affiliate links. There are 0 products on this site and 0 places on it where money reaches anyone but us.

What happens when a peptide comes up.

01

What the published work actually measured: what, in whom, for how long, and where it falls short. Never the finding on its own.

02

Where the substance sits with FDA in a named document, with the date that document was read written next to it.

03

The known risks, in the same breath as the potential upside, rather than in a footnote under it.

04

What to ask a prescriber — and which of those questions a prescriber may not be able to answer either.

05

Where the honest answer is that nobody knows yet, that is the answer you get.

What does not happen: a dose, a source, a brand, a protocol, or a recommendation to take anything. Virtual Vitalis writes 0 prescriptions and supplies 0 medications, and there is no tier of service in which that changes.

Three words that get used as if they meant the same thing.

Most of the confusion in this category is one substitution, repeated. Approved, unrestricted and safe are three separate findings, and a substance can hold any one of them without the other two.

approved

a regulator reviewed an application and authorised the drug for a stated use

unrestricted

no list currently restricts it, which is the absence of a finding

safe

somebody measured harm and did not find it, in people, for long enough

Removal from a restriction list is the one most often read as the other two. It usually means a procedural step has occurred, and it is not a statement that the safety question was answered. A substance can be off every list, have 0 approved uses, and still be a thing nobody has studied in enough people for long enough.

There are 3 lawful routes.

FDA names three routes by which a bulk substance may be used in compounding under section 503A, and a substance can miss all three. This is the framework the whole argument runs on, and almost nobody arguing about it in public has read it.

01

It complies with a United States Pharmacopeia or National Formulary monograph, if one exists.

02

It is a component of an FDA-approved drug product, if no such monograph exists.

03

It appears on FDA's 503A bulks list, if neither of the first two applies.

A substance meeting none of the three is not thereby banned and not thereby permitted. It is outside the framework — which is harder to explain than either answer, and is the reason the question “is it legal?” has no short one.

“Research use only” is a sentence on a label.

It is not a category of permission, and FDA has said so in writing to sellers who relied on it. Under section 201(g)(1) of the Federal Food, Drug, and Cosmetic Act a product is a drug because of its intended use, and intended use is read from the whole page: the description, the claims, and what sits in the cart beside it.

That doctrine applies to this page as much as to a seller's. It is one of the reasons there is no price, no button and no product anywhere on it.

The example this site is built on.

The molecule turning on the homepage is BPC-157. A site whose whole position is that it does not hide things cannot show an unlabelled molecule for six screens, so it is named — and naming it obliges us to say where it actually stands.

Read the paragraph below twice, and note what it does not say. FDA does not say the compound is dangerous. FDA does not say it is fine. FDA says it lacks the information to know, which is a third thing, and it is the thing almost nobody quoting this page in either direction reports.

On the page that paragraph comes from, BPC-157 appears under the heading “Bulk drug substances nominated but withdrawn” rather than in the table of substances currently in category 2. FDA's own line for that section is that the nominations were withdrawn by the nominators. A withdrawn nomination is a procedural event. It is not a safety finding, in either direction.

substance

BPC-157

Drugs@FDA records, 17 Aug 2026

0

same query, semaglutide

returns a record — which is how we know the query works

RCSB PDB entries, 16 Aug 2026

0

same search, insulin

12,860

FDA page read

17 Aug 2026, page stamped current as of 22 Apr 2026

Two searches, each with a control, each re-runnable by you in about a minute. That is deliberate: a number with no control behind it is a number you are being asked to trust, and this page would rather be checked than believed.

Questions worth taking to a prescriber.

These are questions, not recommendations. None of them implies that anyone should take anything, and a good answer to all of them is still not a reason to.

01

What has been measured in humans — how many people, for how long, and measuring what?

02

What is the evidence that the thing measured is the thing I care about?

03

What would change your mind, and what result would count as this not working?

04

What are the known risks, and what is simply unstudied rather than known to be safe?

05

Who makes it, to what standard, and who has tested that this vial contains what the label says?

06

What do you gain if I say yes, and would you tell me if you did?

The last one is the one people skip. It is also the only question on the list whose answer is checkable without a laboratory.

Where this stops.

Virtual Vitalis writes 0 prescriptions, supplies 0 medications and makes 0 diagnoses. That line usually lives in a footer. It is in the body of this page because it is not a caveat on the product — it is the product.

Keep your clinician. Bring them better questions.

This page is education, not medical or legal advice, and it is not a recommendation to take, obtain, or avoid anything. It is written by people who are not your clinician and are not lawyers. Decisions about your health belong with you and a licensed clinician who knows your history.